Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/ HER2– advanced or metastatic breast cancer in Spain
- Galve-Calvo, E.
- González-Haba, E.
- Gostkorzewicz, J.
- Martínez, I.
- Pérez-Mitru, A.
Aldizkaria:
ClinicoEconomics and Outcomes Research
ISSN: 1178-6981
Argitalpen urtea: 2018
Alea: 10
Orrialdeak: 773-790
Mota: Artikulua
